Georg A. Halder
Leuven, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Steatotic liver disease induces YAP/TAZ-driven cell competition that can suppress tumor initiation.
Journal: Journal of hepatology
Published: December 20, 2024
In Vivo Tracking and 3D Mapping of Cell Death in Regeneration and Cancer Using Trypan Blue.
Journal: Cells
Published: June 11, 2024
Expected and unexpected effects after systemic inhibition of Hippo transcriptional output in cancer.
Expected and unexpected effects after systemic inhibition of Hippo transcriptional output in cancer.
Journal: Nature communications
Published: January 05, 2023
Hippo signaling instructs ectopic but not normal organ growth.
Journal: Science (New York, N.Y.)
Published: November 17, 2022
A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
Journal: Molecular cancer therapeutics
Published: November 04, 2022
Shared enhancer gene regulatory networks between wound and oncogenic programs.
Journal: eLife
Published: June 17, 2022
Initiation of hepatic stellate cell activation extends into chronic liver disease.
Journal: Cell death & disease
Published: July 27, 2021
A Mouse Model of Cholangiocarcinoma Uncovers a Role for Tensin-4 in Tumor Progression.
Journal: Hepatology (Baltimore, Md.)
Published: August 04, 2020
Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice.
Journal: Science (New York, N.Y.)
Published: February 12, 2019
Last Updated: 09/26/2026